Imunon Faces Nasdaq Delisting Due to Non-Compliance

Imunon ( (IMNN) ) just unveiled an announcement.

Imunon, Inc. has received a delisting determination from Nasdaq due to non-compliance with the minimum bid price and stockholders’ equity requirements. The company plans to appeal the decision and may implement a reverse stock split to regain compliance, but there is no assurance of success. Delisting could impact stock trading and capital raising.

The most recent analyst rating on (IMNN) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Imunon stock, see the IMNN Stock Forecast page.

Spark’s Take on IMNN Stock

According to Spark, TipRanks’ AI Analyst, IMNN is a Neutral.

Imunon’s financial instability, characterized by negative revenue and cash flow metrics, significantly impacts its overall stock score. Technical indicators suggest caution, with bearish trends and lack of momentum. Though the recent earnings call highlights promising clinical progress, concerns about cash runway and funding remain. Valuation metrics further reflect the stock’s risky profile, with a negative P/E ratio and no dividend yield.

To see Spark’s full report on IMNN stock, click here.

More about Imunon

Average Trading Volume: 9,572,535

Technical Sentiment Signal: Buy

Current Market Cap: $34.91M

For detailed information about IMNN stock, go to TipRanks’ Stock Analysis page.